logo
logo
VNDA stock ticker logo

Vanda Pharmaceuticals Inc.

NASDAQ•VNDA
CEO: Dr. Mihael H. Polymeropoulos M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2006-04-12
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Contact Information
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC, 20037, United States
202-734-3400
www.vandapharma.com
Market Cap
$520.74M
P/E (TTM)
-2.4
17.5
Dividend Yield
--
52W High
$9.94
52W Low
$3.81
52W Range
82%
Rank35Top 29.9%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$57.22M+0.00%
4-Quarter Trend

EPS

-$2.39+0.00%
4-Quarter Trend

FCF

-$29.52M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Fanapt Sales Surge Fanapt net product sales reached $117.3M, showing 24% growth versus prior year results for 2025.
Total Revenue Growth Total net product sales grew 9% to $216.1M for fiscal year 2025, despite HETLIOZ sales decline.
NEREUS Regulatory Approval NEREUS received FDA approval in December 2025 for preventing vomiting induced by motion in adults.
Strong Cash Position Maintained $263.8M in total cash and marketable securities at year-end 2025, supporting operations.

Risk Factors

HETLIOZ Generic Competition HETLIOZ net sales declined 7% to $71.4M due to generic competition and elevated specialty pharmacy inventory levels.
Significant Operating Losses Significant operating losses continued, resulting in a net loss of $(220.5M) for the fiscal year 2025.
R&D and SG&A Spending R&D expenses rose 47% to $109.3M and SG&A increased 63% due to commercial investments.
Pipeline Approval Uncertainty Future commercial success hinges on obtaining regulatory approvals for pipeline candidates like Bysanti and Imsidolimab.

Outlook

Bysanti FDA Decision Pending Bysanti NDA for bipolar I/schizophrenia under FDA review; decision expected February 21, 2026 PDUFA date.
Advancing Key Pipeline Studies Submitted Imsidolimab BLA for GPP in Q4 2025; Phase III studies ongoing for VQW-765 and Bysanti MDD.
NEREUS Phase III Planning Anticipate initiating Phase III program for NEREUS in GLP-1 induced nausea/vomiting in the first half of 2026.
Continued Commercial Investment Maintain strategic investments in commercial infrastructure supporting Fanapt and future product launches.

Peer Comparison

Revenue (TTM)

VNDA stock ticker logoVNDA
$216.11M
+8.7%
ARCT stock ticker logoARCT
$74.12M
-46.4%
SCPH stock ticker logoSCPH
$49.97M
+107.8%

Gross Margin (Latest Quarter)

VNDA stock ticker logoVNDA
93.3%
+0.1pp
ARCT stock ticker logoARCT
77.9%
-19.5pp
VYGR stock ticker logoVYGR
73.5%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CAPR$1.40B-14.2-91.0%0.0%
ALLO$548.34M-2.8-57.1%18.0%
VNDA$520.74M-2.4-49.2%2.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.6%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:May 5, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data